FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014743208> ?p ?o ?g. }

• W2014743208 endingPage "200" @default.
• W2014743208 startingPage "193" @default.
• W2014743208 abstract "Background Several studies implicated that lung cancer progression was governed by the interaction between estrogen receptor (ER) and epidermal growth factor receptor (EGFR) signaling pathways. Combined targeting of EGFR and ER may have the synergistic effect in lung cancer treatment. The aim of this study was to explore the potential utility of inhibiting these two pathways with combination of anastrozole and gefitinib in non-small cell lung cancer (NSCLC) cell lines. Materials and methods The expression levels of ER (ER-α and ER-β) in lung cancer cell lines (A549, H460, SPC-A-1, H1299) and normal bronchus epithelial cell BEAS-2B were detected using real-time PCR and Western blot. Immunocytochemistry was used to locate ER-α and ER-β in cell line with highest ER expression levels. The cells were treated with anastrozole or gefitinib alone or in combination. The cell proliferation inhibition was detected by the CCK8 assay, cell cycle and apoptosis effects were detected by flow cytometry; the expression levels of phosphorylated-EGFR (p-EGFR), ERK, phosphorylated-ERK (p-ERK), AKT and phosphorylated-AKT (p-AKT) were detected by Western blot. Results Among these cell lines the expression levels of ER in A549 cells were highest. In A549 cell line, ER-α was mainly localized in the cytoplasm, whereas ER-β was mainly localized in the cytoplasm and to a lesser degree in the nucleus. The combination of two drugs increased the proliferation inhibition rates for 24 h, 48 h, 72 h to 37.66 ± 1.02%, 63.41 ± 2.02%, 70.50 ± 0.86%, respectively, which was closely associated with elevation of the G0/G1 phase fraction (P < 0.05). Apoptosis rates of A549 cells treated with anastrozole, gefitinib alone or in combination were 10.72 ± 1.12%, 17.40 ± 1.28%, 23.02 ± 2.32%, respectively (P < 0.05). The synergistic effects of the combination therapy were accompanied by reduction of p-EGFR, p-ERK and p-AKT expression compared with individual treatment. Conclusions The results of this study suggest that the combination of anastrozole and gefitinib compared with either drug alone can maximally inhibit cell proliferation, induce apoptosis, and affect downstream signaling pathways. Our study supports functional interaction between the ER and the EGFR pathways in lung cancer and provides a clinically exploitable strategy for non-small cell lung cancer patients." @default.
• W2014743208 created "2016-06-24" @default.
• W2014743208 creator A5015779745 @default.
• W2014743208 creator A5016020113 @default.
• W2014743208 creator A5024764911 @default.
• W2014743208 creator A5027378939 @default.
• W2014743208 creator A5036977660 @default.
• W2014743208 creator A5037204705 @default.
• W2014743208 creator A5077357809 @default.
• W2014743208 creator A5085113015 @default.
• W2014743208 creator A5088242164 @default.
• W2014743208 date "2012-12-01" @default.
• W2014743208 modified "2023-09-23" @default.
• W2014743208 title "The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines" @default.
• W2014743208 cites W1963523217 @default.
• W2014743208 cites W1969658446 @default.
• W2014743208 cites W1989069744 @default.
• W2014743208 cites W1991378725 @default.
• W2014743208 cites W2001882859 @default.
• W2014743208 cites W2004943516 @default.
• W2014743208 cites W2006985579 @default.
• W2014743208 cites W2010311297 @default.
• W2014743208 cites W2031056915 @default.
• W2014743208 cites W2043911313 @default.
• W2014743208 cites W2049274590 @default.
• W2014743208 cites W2064977504 @default.
• W2014743208 cites W2081725472 @default.
• W2014743208 cites W2082531495 @default.
• W2014743208 cites W2112304698 @default.
• W2014743208 cites W2112780046 @default.
• W2014743208 cites W2121522838 @default.
• W2014743208 cites W2122553809 @default.
• W2014743208 cites W2122931235 @default.
• W2014743208 cites W2126666993 @default.
• W2014743208 cites W2140897623 @default.
• W2014743208 cites W2142862394 @default.
• W2014743208 cites W2145635871 @default.
• W2014743208 cites W2148788638 @default.
• W2014743208 cites W2153631705 @default.
• W2014743208 cites W2170728568 @default.
• W2014743208 cites W4249334806 @default.
• W2014743208 doi "https://doi.org/10.1016/j.lungcan.2012.08.012" @default.
• W2014743208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22985911" @default.
• W2014743208 hasPublicationYear "2012" @default.
• W2014743208 type Work @default.
• W2014743208 sameAs 2014743208 @default.
• W2014743208 citedByCount "30" @default.
• W2014743208 countsByYear W20147432082013 @default.
• W2014743208 countsByYear W20147432082014 @default.
• W2014743208 countsByYear W20147432082015 @default.
• W2014743208 countsByYear W20147432082016 @default.
• W2014743208 countsByYear W20147432082017 @default.
• W2014743208 countsByYear W20147432082018 @default.
• W2014743208 countsByYear W20147432082019 @default.
• W2014743208 countsByYear W20147432082020 @default.
• W2014743208 countsByYear W20147432082021 @default.
• W2014743208 crossrefType "journal-article" @default.
• W2014743208 hasAuthorship W2014743208A5015779745 @default.
• W2014743208 hasAuthorship W2014743208A5016020113 @default.
• W2014743208 hasAuthorship W2014743208A5024764911 @default.
• W2014743208 hasAuthorship W2014743208A5027378939 @default.
• W2014743208 hasAuthorship W2014743208A5036977660 @default.
• W2014743208 hasAuthorship W2014743208A5037204705 @default.
• W2014743208 hasAuthorship W2014743208A5077357809 @default.
• W2014743208 hasAuthorship W2014743208A5085113015 @default.
• W2014743208 hasAuthorship W2014743208A5088242164 @default.
• W2014743208 hasConcept C121608353 @default.
• W2014743208 hasConcept C126322002 @default.
• W2014743208 hasConcept C2776256026 @default.
• W2014743208 hasConcept C2779438470 @default.
• W2014743208 hasConcept C2780580887 @default.
• W2014743208 hasConcept C29537977 @default.
• W2014743208 hasConcept C502942594 @default.
• W2014743208 hasConcept C530470458 @default.
• W2014743208 hasConcept C55493867 @default.
• W2014743208 hasConcept C57074206 @default.
• W2014743208 hasConcept C62112901 @default.
• W2014743208 hasConcept C62478195 @default.
• W2014743208 hasConcept C71924100 @default.
• W2014743208 hasConcept C75217442 @default.
• W2014743208 hasConcept C81729549 @default.
• W2014743208 hasConcept C84606932 @default.
• W2014743208 hasConcept C86803240 @default.
• W2014743208 hasConcept C95444343 @default.
• W2014743208 hasConceptScore W2014743208C121608353 @default.
• W2014743208 hasConceptScore W2014743208C126322002 @default.
• W2014743208 hasConceptScore W2014743208C2776256026 @default.
• W2014743208 hasConceptScore W2014743208C2779438470 @default.
• W2014743208 hasConceptScore W2014743208C2780580887 @default.
• W2014743208 hasConceptScore W2014743208C29537977 @default.
• W2014743208 hasConceptScore W2014743208C502942594 @default.
• W2014743208 hasConceptScore W2014743208C530470458 @default.
• W2014743208 hasConceptScore W2014743208C55493867 @default.
• W2014743208 hasConceptScore W2014743208C57074206 @default.
• W2014743208 hasConceptScore W2014743208C62112901 @default.
• W2014743208 hasConceptScore W2014743208C62478195 @default.
• W2014743208 hasConceptScore W2014743208C71924100 @default.
• W2014743208 hasConceptScore W2014743208C75217442 @default.

• next